Foghorn Therapeutics (NASDAQ:FHTX)報告季度每股虧損$(1.58)，優於分析師預期的$(1.61)，超出1.86%。相比去年同期每股虧損$(2.34)，增加了32.48%。公司報告季度銷售額爲$2260.2萬，低於分析師預期的$3071.3萬，低於預期26.41%。相比去年同期的$3415.5萬，減少了33.83%。

以上內容來自Benzinga Earnings專欄，原文如下：

Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $(1.61) by 1.86 percent. This is a 32.48 percent increase over losses of $(2.34) per share from the same period last year. The company reported quarterly sales of $22.602 million which missed the analyst consensus estimate of $30.713 million by 26.41 percent. This is a 33.83 percent decrease over sales of $34.155 million the same period last year.